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Abstract
STK17A is a relatively uncharacterized member of the death-associated protein family of serine/threonine kinases
which have previously been associated with cell death and apoptosis. Our prior work established that STK17A is a
novel p53 target gene that is induced by a variety of DNA damaging agents in a p53-dependent manner. In this study
we have uncovered an additional, unanticipated role for STK17A as a candidate promoter of cell proliferation and
survival in glioblastoma (GBM). Unexpectedly, it was found that STK17A is highly overexpressed in a grade-
dependent manner in gliomas compared to normal brain and other cancer cell types with the highest level of
expression in GBM. Knockdown of STK17A in GBM cells results in a dramatic alteration in cell shape that is
associated with decreased proliferation, clonogenicity, migration, invasion and anchorage independent colony
formation. STK17A knockdown also sensitizes GBM cells to genotoxic stress. STK17A overexpression is associated
with a significant survival disadvantage among patients with glioma which is independent of age, molecular
phenotype, IDH1 mutation, PTEN loss, and alterations in the p53 pathway and partially independent of grade. In
summary, we demonstrate that STK17A provides a proliferative and survival advantage to GBM cells and is a
potential target to be exploited therapeutically in patients with glioma.
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Introduction
Gliomas are the most frequent primary brain tumors and
include a variety of histological types based on morphological
criteria and are graded on a scale of I-IV [1]. The most common
and lethal gliomas are grade IV astrocytoma called
glioblastoma (GBM). The median survival of patients with GBM
treated with the standard surgery, radiation and temozolomide
is 12-15 months [2-5]. Clearly more effective therapies are
needed and identification of new molecular targets is one key
strategy to achieve this goal.
Gliomas exhibit frequent distinct alterations in genetic
pathways including those of p53, NF1, PTEN, IDH1, EGFR and
PDFGR [6,7]. The p53 pathway is frequently compromised in
gliomas due to mutations in p53, deletion of CDKN2A, or
amplification of MDM2/MDM4 [8]. GBM is also classified into 4
different subtypes (classical, mesenchymal, proneural and
neural) based on gene expression profiling [9]. Drugs that
target known genetic abnormalities in glioma and GBM have
failed to show significant clinical utility [10]. For example, the
EGFR receptor resides on chromosome 7 and is commonly
amplified in GBM yet clinical benefits of EGFR inhibitors have
been limited [11]. Uncovering new and previously unrecognized
molecular targets altered in GBM may provide opportunities to
improve the outcome of patients with malignant high-grade
gliomas.
STK17A is a member of the death associated protein (DAP)
family of serine/threonine protein kinases which includes the
prototypic family member DAPK1, along with DAPK2 and
DAPK3 (ZIPK) [12-14]. STK17A (DRAK1) and STK17B
(DRAK2) are more distantly related and less characterized
members of the DAPK family [12-14]. DAPK1 is a multi-domain
cytosolic actin filament-associated calcium/calmodulin-
dependent, serine/threonine kinase that has a known
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regulatory role in cytoskeletal dynamics, apoptosis, autophagy,
cell adhesion and motility [15-17]. DAPK1 is also a proposed
tumor suppressor gene [16]. Other than the regulatory light
chain of myosin II (MLC), the key in vivo substrates of DAPK1
are unclear [12]. In contrast to DAPK1, very little is known
about the biological role of STK17A. Although possessing
moderate homology in the catalytic kinase domain, STK17A
lacks many of the regulatory domains of DAPK1 including the
death domain and the Ca2+/calmodulin regulatory domain
[12-14]. We have previously shown that STK17A is a direct p53
target gene that plays a role in cisplatin-mediated toxicity of
testicular cancer cells in association with regulation of reactive
oxygen species (ROS) [18].
Here we provide evidence for an unanticipated oncogenic
role for STK17A in glioma. STK17A was highly expressed in a
grade-dependent manner in gliomas when compared to normal
brain. Interestingly, knockdown of STK17A in GBM cells results
in a dramatic alteration in cell shape that is associated with
decreased proliferation, clonogenicity, migration, invasion and
anchorage independent colony formation. Importantly, STK17A
knockdown also sensitized GBM cells to genotoxic stress and
STK17A overexpression was associated with a significant
survival disadvantage among patients with glioma. These data
support a role for STK17A as a new, previously unrecognized
kinase target in GBM.
Results
STK17A is highly expressed in GBM and human GBM
cell lines
Based on our prior interest in STK17A as a novel p53 target
gene, in silico analysis was performed to determine whether
STK17A expression was deregulated in human cancers.
Unexpectedly, the most significant alteration found was
prominent overexpression of STK17A in human glioma. In the
Oncomine database 5 out of 7 studies documented high
STK17A expression in GBM compared to normal brain (2.9-fold
to 7.0-fold increase) (Figure 1A and Figure S1) [19-22]. An
additional study indicated a 4.8-fold increase in STK17A
expression in anaplastic oligodendroglioma compared to
normal brain (Figure S1) [23]. Further, the Cancer Cell Line
Encyclopedia (CCLE) database demonstrated that of 1062 cell
lines representing 37 distinct cancer types, glioma cell lines
express the highest levels of STK17A (Figure S1) [24]. These
findings based on microarray gene expression data were
confirmed by directly assessing STK17A mRNA and protein
expression which demonstrated substantial overexpression (up
to 20-fold) of STK17A in GBM cell lines compared to non-GBM
cancer cell lines originating from other organs and normal brain
(Figure 1B, Figure 2 and Figure S2). Note that some but not all
cells lines demonstrate two prominent bands in Western
analysis. The lower band was validated as representing
STK17A based on its sensitivity to shRNA inhibition and our
finding that overexpression of STK17A increases the intensity
of this lower band (Figure 2, Figure 3 and Figure 4). We also
confirmed that STK17A mRNA levels were increased in GBM
tumor tissue compared to STK17A levels in normal brain
(Figure 1C).
STK17A knockdown in GBM cells results in decreased
cell proliferation, morphological changes, actin stress
fiber formation, and inhibition of cell motility/invasion
To assess the importance of STK17A in GBM cell
proliferation, GBM cells with stable shRNA knockdown of
STK17A were generated. In U87, SF268, U118, A172, and
U563 GBM lines knockdown of STK17A results in substantial
decreased cell proliferation (Figure 3 and Figure S3). The
decreased proliferation was associated with a consistent
change in morphology such that cells became less spindle
shaped and assumed a larger, more rounded and flattened
appearance (Figure 4 and Figure S4). Interestingly
overexpression of STK17A in GBM cells resulted in an
exaggerated spindle-like phenotype as the cells became
elongated, needle shaped and appeared more three-
dimensional than wild-type cells (Figure 4E, Figure S4). The
phenotype of STK17A knockdown and overexpressing GBM
cells is consistent with the known role of the Drosophila
ortholog of STK17A, DRAK, in regulating cell shape, actin/
myosin dynamics and cytoskeletal changes [25-27].
Interestingly, knockdown of STK17A in GBM cells resulted in
increased formation of actin stress fibers (Figure 5A). A similar
phenotype was seen in A172 cells (data not shown). Changes
in morphology, actin dynamics, and cell shape were associated
with a decrease in cell motility and invasion of U87 cells (Figure
5B). The inhibition of motility and invasion occurred after 24
hours. In this timeframe effects of STK17A knockdown on
proliferation were minimal indicating that the decline in motility
and invasion was not due to a decrease in cell proliferation
(Figure S5). Interestingly, although STK17A-sh1 is less
effective in reducing expression of STK17A as compared to
STK17A-sh2, it is more effective at reducing migration and
invasion. In contrast, an increase in motility or migration was
not detected when STK17A was overexpressed in U87 cells
(data not shown). This suggests that U87 cells may already be
optimally invasive and motile or that the high basal levels of
STK17A in U87 cells is already saturating for motility and
invasion. An alternate explanation is that STK17A may be
necessary but not sufficient to alter invasion and/or motility.
STK17A knockdown in GBM decreases clonogenic and
anchorage-independent cell growth and increases
sensitivity to DNA damaging agents
Since STK17A is highly expressed in GBM, the effect of
STK17A knockdown on the oncogenic properties of GBM cells
was assessed. Knockdown of STK17A caused a substantial
reduction in soft agar clone formation and clonogenicity of U87,
SF268, A172 and U118 cells (Figure 6, Figure S6 and Figure
S7). In addition, knockdown of STK17A sensitized U251 and
U87 GBM cells to the DNA damaging agent cisplatin and U87
cells to temozolomide, while overexpression of STK17A in U87
cells resulted in resistance to cisplatin (Figure 6 and Figure
S8A). Interestingly, U251 has mutant p53 while U87 has wild-
type p53 yet both cell lines are sensitized to cisplatin upon
STK17A knockdown. This suggests that the effects of STK17A
on sensitivity to cisplatin can occur in the presence or absence
of wild-type p53 in GBM cells. This finding is consistent with
data generated from a recent systematic analysis of genetic
STK17A in Glioma
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Figure 1.  STK17A is overexpressed in GBM.  A, Data from Sun Brain [19], and TCGA Brain (https://tcga-data.nci.nih.gov/tcga/
tcgaHome2.jsp) comparing microarray-based STK17A expression from clinical nonmalignant brain specimens (Norm. Brain) and
clinical GBM indicating high expression of STK17A in GBM. B, Real-time PCR analysis of STK17A expression in GBM cell lines
compared to expression in other cancer types and normal brain. Expression is normalized to GAPDH. Bars are the average of
triplicate or duplicate biological replicates except for normal brain RNA which is the average of technical duplicates. Error bars are
SD. All cell lines are human. Non-GBM cell lines are as follows: NT2 (NT2/D1), embryonal carcinoma; U2OS, osteosarcoma; H23,
A549, and Hop62, lung adenocarcinomas; MCF7, breast cancer. C, Real-time PCR analysis of STK17A expression in normal brain
mRNA and four clinical GBM samples from Dartmouth Hitchcock Medical Center. Expression is normalized to GAPDH. The bars
represent the averages of technical duplicate determinations.
doi: 10.1371/journal.pone.0081803.g001
STK17A in Glioma
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Figure 2.  STK17A protein is overexpressed in GBM cells lines compared to NT2/D1 and HCT116 cells.  A, B, Western
analysis comparing STK17A expression in U87, U251, U118 and U563 GBM cells compared to NT2/D1 human embryonal
carcinoma and HCT116 colon cancer cells. Arrow indicates STK17A specific band identified by the diminished signal in U87 cells
stably expressing STK17A shRNA.
doi: 10.1371/journal.pone.0081803.g002
STK17A in Glioma
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Figure 3.  STK17A knockdown results in decreased GBM cell proliferation.  U87, SF268 and U118 GBM cells stably
expressing STK17A shRNA or a control shRNA were assessed for changes in cell proliferation by cell counting 4.5 days after
plating. Cell counts were normalized to cell counts after 0.5 days of plating to control for plating errors and differences in cell
adherence. Bars are the average of three biological replicates and error bars are SD. *, p < 0.05. Data are representative of at least
two independent experiments. To the right of each graph the extent of STK17A knockdown was assessed by Western analysis.
doi: 10.1371/journal.pone.0081803.g003
STK17A in Glioma
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Figure 4.  Knockdown or overexpression of STK17A alters cell morphology of U87 cells.  Representative micrographs of
parental U87 cells (A), U87 cells stably expressing control shRNA (B), two distinct STK17A shRNAs (C, D), or U87 cells stably
overexpressing STK17A (E). Cells become large, flatter and more rounded upon STK17A knockdown while cells take on an
elongated, needle-shaped appearance upon STK17A overexpression. Representative of three independent derivations of each cell
line. Pictures were taken at 10X magnification on a NIKON ELWD microscope. F, Western analysis of STK17A knockdown and
overexpression. Efficiency of stable knockdown is depicted in Figure 3.
doi: 10.1371/journal.pone.0081803.g004
STK17A in Glioma
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Figure 5.  STK17A knockdown results in the formation of actin stress fibers and inhibition of cell motility and invasion.  A,
Representative fluorescent images of U87 cells stably expressing control shRNA and two distinct STK17A shRNAs. Actin is stained
green and nuclei are stained blue. Note the larger size of STK17A knockdown cells and the presence of actin stress fibers. Extent of
knockdown is depicted in Figure 3. This morphologic phenotype was apparent in independent derivations of the cell lines. Pictures
were taken at 20X magnification on a NIKON ELWD fluorescent microscope. B, STK17A knockdown decreases cell migration and
invasion of U87 cells. Cell migration and invasion was assessed as described in Methods. Bars are the average of biological
triplicates and error bars are SD. *, p < 0.05. Representative of two independent experiments.
doi: 10.1371/journal.pone.0081803.g005
STK17A in Glioma
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markers of drug resistance in cancer cells which found cisplatin
resistance associated with high levels of STK17A expression in
a panel of nervous system derived tumor cell lines which
included glioma, medulloblastoma and neuroblastoma lines
(Figure S8B) [28]. High levels of STK17A expression were also
associated with resistance to BID1870 (RSK, PLK1, AURKB
inhibitor; 2.0-fold), AZD7762 (CHK1/2 inhibitor, 2.9-fold) and
PD0332991 (CDK4/6 inhibitor, 2.1-fold) [28]. These data
indicate that STK17A may play a role in promoting
tumorigenicity and resistance to chemotherapeutics in GBM
cells.
STK17A expression increases with glioma grade and is
associated with decreased patient survival
In order to assess the clinical relevance of STK17A
overexpression in glioma, further analysis was performed using
publically available datasets. Three distinct datasets revealed
that STK17A expression increases progressively with glioma
grade and is highest in the most aggressive and lethal grade IV
glioma (GBM) (Figure 7A). Increased expression of STK17A
was associated with a highly significant decrease in overall
patient survival when assessed by the Kaplan-Meier log-rank
test in a combined cohort of all patients with glioma from the
TCGA database (Figure 7B). Glioma patients were divided at
the median STK17A expression level for this analysis. STK17A
resides on chromosome 7 approximately 12 MB from EGFR
which is frequently amplified in gliomas [11]. While high
STK17A expression is associated with poor survival in glioma,
similar analysis did not find an association between high EGFR
expression and survival in the same cohort (Figure 7B).
Univariant Cox proportional analysis using STK17A and EGFR
expression as continuous variables also indicated that high
STK17A (Hazard Ratio (HR) = 2.07, p value = 5.48 x 10-7), but
not high EGFR (HR = 1.07, p value = 0.17), was associated
with poor survival (Table A in Table S1). To assess
confounding effects associated with STK17A expression,
multivariant Cox proportional analysis was performed with age,
EGFR level, gender and grade as confounding variables. Since
STK17A is expressed in a grade-depended manner (Figure
7A), it was not surprising that grade was a partially confounding
variable. However, STK17A expression still independently
predicted survival after correcting for grade, albeit with a lower
HR and p value (Table B in Table S1). STK17A expression
also predicted overall survival after correcting for age, gender
and EGFR expression (Table B in Table S1).
Kaplan-Meier analysis was repeated with a TCGA cohort
containing only low grade gliomas (II and III). STK17A
expression, but not EGFR expression, again significantly
predicted overall patient survival (Figure 7B) and STK17A
expression was again shown to be a predictor of survival (HR =
2.29) when corrected for grade, age and EGFR expression
upon univariant and multivariant Cox analysis (Table C and
Table D in Table S1). STK17A expression did however lose
predictive power in a TCGA cohort of only GBM patients which
more uniformly express high levels of STK17A. Although
Kaplan-Meier analysis still indicated borderline significance of
STK17A as a predictor of survival in GBM (Figure 7B) and Cox
analysis indicated a significant association between STK17A
expression and survival even after correcting for EGFR, gender
and molecular phenotype, the HR values were lower as
compared to the LGG cohort and significance was lost when
correcting for age (Table E and Table F in Table S1). Together
the data suggests that STK17A is an independent predictor of
survival in glioma patients, but since STK17A expression is
highly grade-dependent, grade is likely a partially confounding
factor.
Further analysis performed within the low grade glioma
cohort indicated that STK17A remains a significant predictor of
survival after correcting for the common genetic glioma
alterations of IDH1 mutation and PTEN loss (Table G and
Table H in Table S1). Further the p53 target gene STK17A
remained a predictor of survival after correction for p53
pathway disruption due the p53 mutation, loss of CDKN2A, and
amplification of MDM2 and MDM4 (Table G and Table H in
Table S1). We were unable to detect any significant trends in
STK17A expression associated with p53 pathway alterations
except for deletion of CDKN2A (P19ARF). Low grade glioma
and high grade GBM tumors with homologous deletion of
CDKN2A had significantly higher levels of STK17A, suggesting
that those tumors with deactivation of p53 due to CDKN2A loss
may compensate by upregulating STK17A (Figure S9).
Discussion
GBM is a devastating disease with high lethality despite
current treatment modalities [2,5]. Here we have identified
STK17A as a novel candidate kinase target in gliomas.
Evidence that STK17A promotes glioma progression and
survival includes the finding that STK17A is highly
overexpressed in a grade-dependent manner in tumor
compared to normal brain and other tumor types and that
STK17A knockdown decreases cell proliferation, soft agar
colony formation and clonogenicity and sensitizes GBM cells to
genotoxic stress. Further, high levels of STK17A were
associated with poor survival in patients with glioma indicating
that STK17A may have clinical relevance as a therapeutic
target in these neoplasms.
We previously showed that STK17A is a p53 target gene and
is induced in a p53-dependent manner in several cell contexts
including testicular cancer cells [18]. Our current and previous
work suggests that STK17A may have context dependent
activities since STK17A was associated with cisplatin
sensitivity in testicular cancer cells which express very low
levels of basal STK17A that is highly induced upon genotoxic
stress [18]. In contract STK17A is highly basally expressed in
GBM cell lines, even in U251, U118 and U563 cells mutant for
p53, and confers chemotherapy resistance. This difference
may relate to the different levels of STK17A or the widely
distinct cell contexts of testicular germ cell cancer compared to
GBM. Another possibility relates to potential activities of
STK17A that are known to be context-dependent. For example,
other kinases in the DAP-family are known to regulate
autophagy which can be pro- or anti-apoptotic depending on
cell context and level of stress [29,30]. It is noteworthy that p53
itself can mediate either chemotherapy resistance or
STK17A in Glioma
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Figure 6.  STK17A knockdown decreases oncogenic properties of GBM cells.  A, STK17A knockdown decreases soft agar
colony formation. U87 control or U87 STK17A knockdown cells were suspended in soft agar and cells were stained with MTT
reagent after 2 weeks of culture. Representative of two independent experiments. B, STK17A knockdown decreases clonogenicity
of GBM cells. U87 control or STK17A U87 knockdown cells were plated and stained with Giemsa after 10 days of cell culture.
Representative of three independent experiments. C, STK17A knockdown sensitizes GBM cells to cisplatin and temozolomide. Left,
Dose response after 3 days of cisplatin treatment of U87 or U251 control versus STK17A knockdown cells. Cell proliferation and
survival was measured with Cell-Titer Glo reagent. Data points are the average of biological triplicates and error bars are SD. *, p <
0.05. Representative of three independent experiments. Right, Dose response after 3 days of temozolomide treatment of U87
control versus U87 STK17A knockdown cells. Cell proliferation and survival was measured with Cell-Titer Glo reagent. Data points
are the average of biological triplicates and error bars are SD. *, p< 0.05. Representative of two independent experiments.
doi: 10.1371/journal.pone.0081803.g006
STK17A in Glioma
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e81803
Figure 7.  STK17A expression in glioma is associated with high grade and decreased survival.  A, Expression data was
downloaded from the Rembrandt and TCGA databases and data from Sun Brain [19] was downloaded from Oncomine and grouped
according to grade. Rembrandt has 21 normal, 99 grade II, 85 grade III and 130 grade IV samples. TCGA has 10 normal, 7 grade II,
20 grade III and 482 grade IV samples and Sun Brain has 26 normal, 45 grade II, 31 grade III and 81 grade IV samples. Error bars
are SEM. *, p < 0.02. B, STK17A expression is associated with poor overall survival in gliomas. Kaplan-Meier log-rank tests were
performed on data obtained from the TCGA database. In all cases high and low expressing groups were divided at the median. All
glioma and low grade glioma expression was from RNA-seq data while GBM expression was from Affymetrix microarray data.
doi: 10.1371/journal.pone.0081803.g007
STK17A in Glioma
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chemotherapy sensitivity depending on the cancer cell context
and level of stress [31,32].
It should be noted that our analysis found an association
between STK17A expression and survival using an unbiased
means of defining high and low STK17A expression as either
above or below the median expression value in each data set
(Figure 7B) or treating STK17A expression as a continuous
variable (Tables A-H in Table S1). Defining high and low EGFR
expression above and below its median expression value failed
to show an association of high EGFR with poor survival in all
glioma, low grade glioma, and GBM. Treating EGFR
expression as a continuous variable only showed a significant
association with poor survival in the low grade glioma dataset
(Tables A-H in Table S1). However bifurcating patients into two
groups, those that either have an EGFR amplification,
activating mutation or overexpression above 2-fold versus
those that do not results in a significant association of the
EGFR gain of function group with poor survival. For low grade
glioma the association has a HR of 2.0, p value = 0.041 and for
GBM the association has a HR of 1.37, p = 0.0033. This result
is consistent with the known association of EGFR gain of
function with poor survival in GBM [11].
In addition to the association of high STK17A expression
with poor patient survival, we have shown in U87 cells that
STK17A knockdown decreases cell invasion and motility and
alters cell shape and actin dynamics. While several molecular
functions of the DAP-family have been proposed, the most
studied is the interaction with the cytoskeleton through
phosphorylation of the regulatory subunit of myosin light chain
(MLC), leading to modulation of actin stress fibers, adhesion
junctions and cell motility [12,15,17,33]. Extending these
findings to STK17A must be taken with caution since STK17A
lacks the cytoskeletal-related regulatory and targeting domains
of DAPK1. However, it is known that STK17A can
phosphorylate MLC in vitro [14]. In addition Drosophila has only
a single DAP kinase like gene called DRAK which is most
closely related to STK17A [27]. Recent genetic evidence
suggests that DRAK is involved in regulating epithelial tissue
morphology, cell shape and adhesion, organ growth and
cytoskeletal dynamics through phosphorylation of the
Drosophila ortholog of MLC (sqh) [25-27]. Further detailed
study will be required to uncover the exact mechanism(s) by
which STK17A regulates cytoskeletal dynamics and cell motility
and to uncover the extent by which these functions impact the
cell proliferation, survival and tumorigenic promoting properties
of STK17A in GBM cells.
In conclusion, this study indicates that STK17A is
overexpressed in gliomas in a manner that corresponds with
increasing tumor grade and malignancy. STK17A also
promotes cell proliferation, survival and resistance to
chemotherapy in GBM cells and STK17A has effects on cell
shape, actin dynamics, invasion and motility. The association
of STK17A expression with patient survival suggests that
STK17A is a potentially important new kinase target in glioma.
In summary, we have uncovered an unrecognized role for
STK17A in glioma biology. Targeting STK17A may lead to the
development of new therapies for GBM and other cancers and
may provide a new strategy to sensitize cancers to existing
therapies.
Materials and Methods
Cell proliferation, soft agar and clonogenicity assays
Cells were cultured in DMEM (Gibco) with 10% FBS. Human
glioblastoma cell lines U87, SNB19, SNB44, SNB75, U118,
U563, A172 and SNB19 were purchased from ATCC. Human
glioblastoma cell line SKMG3 was obtained from Memorial
Sloan Kettering Cancer Center and human glioblastoma cell
lines SF268 and SF767 were from the Brain Tumor Research
Center, University of California San Francisco. Human
osteosarcoma (U2OS), embryonal carcinoma (NT2/D1), breast
cancer (MCF7) and colon cancer (HCT116) were purchased
from ATCC. Human non-small cell cancer cell lines Hop62,
A549 and H23 were obtained from the Developmental
Therapeutics Program at the National Cancer Institute. Cell
proliferation and survival was assessed by manually counting
trypan blue viable cells with a hemocytometer. Plating errors
and differences in cell adherence were controlled for by
normalizing the number of viable cells counted at 4.5 days after
plating with the number of viable cells counted 0.5 days after
plating. Cell proliferation and survival after drug treatment was
assessed with Cell-Titre Glo (Promega). Cisplatin and
temozolomide were purchased from Sigma. Soft agar assays
were performed as previously described [34]. Briefly, cells were
plated in DMEM containing 10% FBS and 0.26% Seakem ME
Agarose (Cambrex Bioscience). A total of 1.5 × 104 viable,
trypan blue-excluding cells were plated per well of a six well
plate. A lower layer of 1% agarose in DMEM and 10% FBS
was used. Cells were cultured every 4 days with fresh media.
After 2 weeks of culture, colonies were stained with a 5-mg/ml
solution of MTT Reagent (Sigma) in PBS. For clonogenic
assays 1.0 × 103 viable, trypan blue-excluding cells were plated
per well of a six well plate. Cells were cultured every 4 days
with fresh media and colonies were fixed in methanol and
stained with Giemsa stain after 10 days.
RNAi knockdown
Lentiviral silencing shRNAs targeting human STK17A
(TRCN0976, STK17A-sh1 and TRCN0975, STK17A-sh2) were
purchased from Open Biosystems along with pLKO.1 control.
The sequence of STK17Ash1 is
AGGCTCTTGAATACTGCTCTG and the sequence for
STK17A-sh2 is TAGTTCAAGTACAGCAATCTC. Lentiviral
stocks were generated from 293T cells as described previously
[35]. GBM cells were cultured with lentiviral stocks for 24 h and
stable pools were selected with 1.0 µg/ml puromycin.
Western analysis and real-time PCR
SYBR green-based real-time PCR (Applied Biosystems) was
employed using the ddCT method normalized to GAPDH.
STK17A primers were 5’-GCTGGGGAGAGCGGGTGTTT-3’
and 5’-CTGGCCGCCTGTTCACTCCG-3’. GAPDH primers
were 5’-GATTCCACCCATGGCAAATT-3’ and 5’-
GATGGTGATGGGATTTCCATTG-3’. For Western analysis
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cells were lysed in radioimmune precipitation buffer and
separated by SDS-PAGE. Antibodies to actin (sc01615, Santa
Cruz), GAPDH (sc47724, Santa Cruz) and STK17A
(IMG-157-1, Imgenex) were used. Despite the effects of
STK17A on cell shape, similar results were obtained when
actin and GAPDH were used to controls for loading (Figure
S2). Archival frozen GBM samples were procured through the
pathology core facility of the Norris Cotton Cancer Center.
These samples were primary tumor tissue sections obtained at
the time of initial surgery and prior to therapy from patients
subsequently diagnosed with type IV GBM. Samples were
processed for RNA extraction by freezing in liquid nitrogen and
pulverizing with a mortar and pestle before dissolving in Tri-
Reagent (Sigma). Normal RNA was purchased from Clontech.
NB26 refers to human fetal brain total RNA (catalog #636526).
NB30 refers to human brain total RNA (catalog #636530).
Migration, invasion assays and actin staining
Invasion (200,000 cells) and migration (50,000 cells) assays
were performed using 6-well 8.0 µM trans-well inserts (BD
Biosciences). For the invasion assay, the inserts were coated
with growth factor reduced matrigel (diluted 1 to 1 with serum
free DMEM). The upper part of the insert was exposed to 1%
FBS and the lower part to 10% FBS. After 24 hours, the upper
part of the insert was cleaned using cotton swabs and the
insert was cut and mounted using DAP1 containing florescent
mounting solution (Vector Biolabs). Cells were counted in ten
random fields using an epiflourescent microscope on 20X
magnification. For the migration assay, the assay was
performed exactly as described above with the exception of
matrigel addition. For actin staining cells were fixed with 4%
paraformaldehyde for 20 minutes and permeabilized with
0.25% Triton-X-100 for 20 minutes. Cells were stained with 50
nM tetramethylrhodamine isothiocyanate (TRITC)-
phalloidin (Sigma) for 1 hour. Cell nuclei were then stained with
DAPI mounting solution. Cells were also plated at 50,000 and
200,000 per 6-well plate and counted with trypan blue 24 hours
later to control for proliferation.
In silco and Survival analysis
STK17A expression from Liang et al., French et al., Murat et
al., and Bredel et al. [20-23] was obtained from Oncomine
(https://www.oncomine.com). STK17A expression in 1062
cancer cell lines was obtained through the Cancer Cell Line
Encyclopedia (http://www.broadinstitute.org/ccle/home). For
expression analysis according to grade, Rembrandt Affymetrix
expression data was downloaded from the CA-integrator
website (https://caintegrator.nci.nih.gov/caintegrator/) and
normalized Agilent expression data for normal brain,
glioblastoma multiforme (GBM) and brain low grade gliomas
(LGG) was downloaded from the TCGA website (https://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp). Clinical and gene
expression data for survival analysis was downloaded from the
TCGA website on April 30, 2013. Kaplan-Meier log-rank tests
were performed using WinSTAT and patients were divided into
low or high expression groups at the median expression value
in all cases. RNA-seq expression data for (GBM) and (LLG)
was combined for Kaplan-Meier analysis of all gliomas.
Analysis for LGG (grade II and III) used RNA-seq data.
STK17A expression for Kaplan-Meier analysis of GBM was in
the form of normalized Affymetrix microarray data. Univariant
and multivariant Cox proportional analysis was performed
using the above datasets in WinSTAT. Multivariant analysis
utilized the direct method. STK17A and EGFR expression were
treated as continuous variables of the log 2 transformed RNA-
seq or normalized Affymetrix data for Cox analysis. Age was
treated as a continuous variable. Information on mutations and
the molecular phenotype of tumors was downloaded from the
cBioPortal website (http://www.cbioportal.org/public-portal/)
which necessitated decreasing the number of patients for Cox
regression since this data was only available for a subset of
LGG and GBM tumors.
Ethics Statement
Use of archival GBM samples was approved by the
Committee for the Protection of Human Subjects at Dartmouth-
Hitchcock Medical Center (CPHS #23445). Approval for use of
samples for research purposes was obtained by written
consent.
Statistics
When a value for statistical significance is provided, a two-
sample, two-tailed t test assuming unequal variance was
performed.
Supporting Information
Figure S1.  STK17A is overexpressed in glioblastoma and
anaplastic oligodendroglioma compared to normal brain.
A, Relative STK17A expression from Liang et al., French et al.,
Murat et al., and Bredel et al. [20-23] demonstrates increased
STK17A expression in GBM and oligodendroglioma (AO)
compared to normal brain. Data was obtained through the
Oncomine database. B, STK17A is highly expressed in glioma
cell lines compared to other cancer types. Data was obtained
through the Cancer Cell Line Encyclopedia (CCLE).
(TIF)
Figure S2.  STK17A protein is overexpressed in GBM cell
lines compared to NT2/D1, U2OS, H23, Hop62 and MCF7
cells. A, B, Western analysis comparing STK17A expression in
U87, SNB44, SNB75, SKMG3, U118, U251 and U563 GBM
cells compared to NT2/D1 human embryonal carcinoma, U2OS
osteosarcoma, H23 and Hop62 lung cancer and MCF7 breast
cancer cells. Arrow indicates STK17A specific band identified
by the diminished signal in U87 cells stably expressing
STK17A shRNA.
(TIF)
Figure S3.  STK17A knockdown results in decreased GBM
cell proliferation. U563 and A172 GBM cells stably
expressing STK17A shRNA or a control shRNA were assessed
for changes in cell proliferation by cell counting 4.5 days after
plating. Cell counts were normalized to cell counts after 0.5
days of plating to control for plating errors and differences in
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cell adherence. Bars are the average of three biological
replicates and error bars are SEM. *, p < 0.01. Note A172 cells
with STK17A knockdown had a borderline significant decrease
in proliferation; p = 0.072. To the right of each graph the extent
of STK17A knockdown was assessed by Western analysis.
(TIF)
Figure S4.  STK17A knockdown or overexpression alters
the morphology of A172 GBM cells. A, Representative
micrographs of parental A172 cells with control shRNA, A172
cells with STK17A shRNA, and A172 cells stably
overexpressing STK17A. Pictures were taken at 10X
magnification on a NIKON ELWD microscope. B, Western
analysis documenting STK17A knockdown and overexpression
in engineered A172 cells.
(TIF)
Figure S5.  STK17A knockdown does not affect U87 cell
proliferation at 24 hours. Cells were plated at a density of
50,000 (A) and 200,000 (B) per 6-well plate to match
conditions of migration and invasion assays, respectively.
Trypan blue excluding cells were manually counted 24 hours
later.
(TIF)
Figure S6.  STK17A knockdown leads to decreased soft
agar colony formation in SF268 GBM cells. SF268 control or
SF268 STK17A knockdown cells were suspended in soft agar
and cells were stained with the MTT assay after 2 weeks of
culture. STK17A knockdown in SF268sh1 cells is depicted in
Figure 3 of the main text.
(TIF)
Figure S7.  Effects of STK17A knockdown on clonogenicity
of GBM cells. Stable control shRNA or STK17A-shRNA cells
were plated and stained with Giemsa stain after 10 days of cell
culture. A, SF268; B, A172; C, U118. Western analysis
documenting STK17A knockdown is depicted in Figure S3 and
in Figure 3 of the main text.
(TIF)
Figure S8.  STK17A overexpression is associated with
resistance to cisplatin. A, U87 control cells or U87 cells
stably overexpressing STK17A were treated with indicated
doses of cisplatin for three days and then cell proliferation and
survival was measured with the Cell-Titer Glo assay. Data
points are the average of biological triplicates and error bars
are SD. B, Data obtained through the Oncomine database from
Garnett et al. [28], demonstrating high levels of STK17A mRNA
are associated with cisplatin resistance in CNS cell lines.
(TIF)
Figure S9.  CDKN2A loss is associated with high STK17A
expression in glioma. TCGA expression data downloaded
from the TCGA database was grouped according to CDKN2A
status. Loss is defined as homologous deletion or mutation. A,
Low grade glioma is expression data in the form of log 2
transformed normalized RNA-seq levels. CDKN2A wild-type
represents 18 samples and CDKN2A loss represents 147
samples. B, Glioblastoma is expression data in the form of
normalized Affymetrix signal. CDKN2A wild-type represents
303 samples and CDKN2A loss represents 225 samples. *, p <
0.001.
(TIF)
Table S1.  Combined files tables (A-H) of Cox proportional
analyses for all glioma, low grade glioma and
glioblastoma. Table A, Univariant Cox proportional analysis
for all glioma overall survival (TCGA). Table B, Multivariant Cox
proportional analysis for all glioma overall survival (TCGA).
Table C, Univariant Cox proportional analysis for low grade
glioma overall survival (TCGA). Table D, Multivariant Cox
proportional analysis for low grade glioma overall survival
(TCGA). Table E, Univariant Cox proportional analysis for
glioblastoma overall survival (TCGA). Table F, Multivariant Cox
proportional analysis for glioblastoma overall survival (TCGA).
Table G, Univariant Cox proportional analysis with genetic
alterations for low grade glioma overall survival (TCGA). Table
H, Multivariant Cox proportional analysis with genetic
alterations for low grade glioma overall survival (TCGA).
(XLSX)
Acknowledgements
The authors would like to thank Timothy J. Gauvin and Henry
N. Higgs from the Department of Biochemistry, Dartmouth
Medical School for help with actin staining and florescence
microscopy. The authors would like to thank C. Harker Rhodes
from the Department of Pathology at Dartmouth Medical
School for help with the procurement and processing of GBM
samples.
Author Contributions
Conceived and designed the experiments: PM GR CEF AG
MAI MJS. Performed the experiments: PM MPH GJR EY JT
AK BB AG MJS. Analyzed the data: PM MPH GJR EY JT AK
BB AG. Contributed reagents/materials/analysis tools: CEF AG
MAI. Wrote the manuscript: PM MJS.
References
STK17A in Glioma
PLOS ONE | www.plosone.org 13 November 2013 | Volume 8 | Issue 11 | e81803
1. Goodengerger ML, Jenkins RB (2005) Genetics of adult glioma. Cancer
Genet 205: 613-621.
2. Tran B, Rosenthal MA (2010) Survival comparison between
glioblastoma multiforme and other incurable cancers. J Clin Neurosci
17: 417-421. doi:10.1016/j.jocn.2009.09.004. PubMed: 20167494.
3. Robertson T, Koszyca B, Gonzales M (2011) Overview and recent
advances in neuropathology. Part 1: Central nervous system tumours.
Pathology 43: 88-92. doi:10.1097/PAT.0b013e3283426e86. PubMed:
21233669.
4. Gupta K, Salunke P (2012) Molecular markers of glioma: an update on
recent progress and perspectives. J Cancer Res Clin Oncol 138:
1971-1981. doi:10.1007/s00432-012-1323-y. PubMed: 23052697.
5. Anton K, Baehring JM, Mayer T (2012) Glioblastoma multiforme:
Overview of current treatment and future perspectives. Hematol Oncol
Clin North Am 26: 825-853. doi:10.1016/j.hoc.2012.04.006. PubMed:
22794286.
6. Cancer Genome Atlas Research Network (2008) Comprehensive
genomic characterization defines human glioblastoma genes and core
pathways. Nature 455: 1061-1068. doi:10.1038/nature07385. PubMed:
18772890.
7. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ et al. (2008) An
integrated genomic analysis of human glioblastoma mutltiforme.
Science 321: 1807-1812. doi:10.1126/science.1164382. PubMed:
18772396.
8. England B, Huang T, Karsy M (2013) Current understanding of the role
and targeting of tumor suppressor p53 in glioblastoma multiforme.
Tumor Biol. In press
9. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y et al. (2010)
Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR,
and NF1. Cancer Cell 17: 98-110. doi:10.1016/j.ccr.2009.12.020.
PubMed: 20129251.
10. Polivka J Jr, Polivka J, Rohan V, Topolcan O, Ferda J (2012) New
molecularly targeted therapies for glioblastoma multiforme. Anticancer
Res 32: 2935-2946. PubMed: 22753758.
11. Hegi ME, Rajakannu P, Weller M (2012) Epidermal growth factor
receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 25:
774-779. doi:10.1097/WCO.0b013e328359b0bc. PubMed: 23007009.
12. Temmerman K, Simon B, Wilmanns M (2013) Structural and functional
diversity in the activity and regulation of DAPK-related protein kinases.
FEBS J. In press
13. Bialik S, Kimchi A (2006) The death-associated protein kinases:
structure, function, and beyond. Annu Rev Biochem 75: 189-210. doi:
10.1146/annurev.biochem.75.103004.142615. PubMed: 16756490.
14. Sanjo H, Kawai T, Akira S (1998) DRAKs, novel serine/threonine
kinases related to death associated protein kinase that trigger
apoptosis. J Biol Chem 273: 29066-29071. doi:10.1074/jbc.
273.44.29066. PubMed: 9786912.
15. Lin Y, Hupp TR, Stevens C (2010) Death-associated protein kinase
(DAPK) and signal transduction: additional roles beyond cell death.
FEBS J 277: 48-57. doi:10.1111/j.1742-4658.2009.07411.x. PubMed:
19878313.
16. Gozuacik D, Kimchi A (2006) DAPK protein family and cancer.
Autophagy 2: 74-79. PubMed: 17139808.
17. Kuo JC, Lin JR, Staddon JM, Hosoya H, Chen RH (2003)
Uncoordinated regulation of stress fibers and focal adhesions by DAP
kinase. J Cell Sci 116: 4777-4790. doi:10.1242/jcs.00794. PubMed:
14600263.
18. Mao P, Hever MP, Niemaszyk LM, Haghkerdar JM, Yanco EG et al.
(2011) Serine/threonine kinase 17A is a novel p53 target gene and
modulator of cisplatin toxicity and reactive oxygen species in testicular
cancer cells. J Biol Chem 286: 19381-19391. doi:10.1074/
jbc.M111.218040. PubMed: 21489989.
19. Sun L, Hui AM, Vortmeyer A, Kotliarov Y, Pastorino S et al. (2006)
Neuronal and glioma-derived stem cell factor induces angiogenesis
within the brain. Cancer Cell 9: 287-300. doi:10.1016/j.ccr.2006.03.003.
PubMed: 16616334.
20. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD et al. (2005) Gene
expression profiling reveals molecularly and clinically distinct subtypes
of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814-5819.
doi:10.1073/pnas.0402870102. PubMed: 15827123.
21. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H et al. (2005)
Functional network analysis reveals extended gliomagenesis pathway
maps and three novel MYC-interacting genes in human gliomas.
Cancer Res 65: 8679-8689. doi:10.1158/0008-5472.CAN-05-1204.
PubMed: 16204036.
22. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T et al. (2008)
Stem cell-related “self-renewal” signature and high epidermal growth
factor receptor expression associated with resistance to concomitant
chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024. doi:
10.1200/JCO.2007.15.7164. PubMed: 18565887.
23. French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer
E et al. (2005) Gene expression profiles associated with treatment
response in oligodendrogliomas. Cancer Res 65: 11335-11344. doi:
10.1158/0008-5472.CAN-05-1886. PubMed: 16357140.
24. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA et
al. (2012) The cancer cell line encyclopedia enables predictive
modeling of anticancer drug sensitivity. Nature 483: 603-607. doi:
10.1038/nature11003. PubMed: 22460905.
25. Robertson F, Pinal N, Fichelson P, Pichaud F (2012) Atonal and EGFR
signaling orchestrate rok- and Drak-dependent adherens junction
remodeling during ommatidia morphogenesis. Development 139:
3432-3441.
26. Kiger AA, Baum B, Jones S, Jones MR, Coulson A et al. (2003) A
functional genomic analysis of cell morphology using RNA interference.
J Biol 2: 27. doi:10.1186/1475-4924-2-27. PubMed: 14527345.
27. Neubueser D, Hipfner DR (2010) Overlapping roles of Drosophila Drak
and Rok kinases in epithelial tissue morphogenesis. Mol Biol Cell 21:
2869-2879. doi:10.1091/mbc.E10-04-0328. PubMed: 20573980.
28. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A et al.
(2012) Systematic identification of genomic markers of drug sensitivity
in cancer cells. Nature 483: 570-575. doi:10.1038/nature11005.
PubMed: 22460902.
29. Zalckvar E, Berissi H, Eisenstein M, Kimchi A (2009) Phosphorylation
of Beclin 1 by DAP-kinase promotes autophagy by weakening its
interactions with Bcl-2 and Bcl-XL. Autophagy. 5: 720-722. doi:10.4161/
auto.5.5.8625. PubMed: 19395874.
30. Inbal B, Bialik S, Sabanay I, Shani G, Kimchi A (2002) DAP kinase and
DRP-1 mediate membrane blebbing and the formation of autophagic
vesicles during programmed cell death. J Cell Biol 157: 455-468. doi:
10.1083/jcb.200109094. PubMed: 11980920.
31. Weller M (1998) Predicting response to cancer chemotherapy: the role
of p53. Cell Tissue Res 292: 435-445. doi:10.1007/s004410051072.
PubMed: 9582400.
32. Peller S (1998) Clinical implications of p53: effect on prognosis, tumor
progression and chemotherapy response. Semin Cancer Biol 8:
379-387. doi:10.1006/scbi.1998.0100. PubMed: 10101803.
33. Wang WJ, Kuo JC, Yao CC, Chen RH (2002) DAP-kinase induces
apoptosis by suppressing integrin activity and disrupting matrix survival
signals. J Cell Biol 159: 169-179. doi:10.1083/jcb.200204050. PubMed:
12370243.
34. Giuliano CJ, Kerley-Hamilton JS, Bee T, Freemantle SJ,
Manickaratnam R et al. (2005) Retinoic acid represses a cassette of
candidate pluripotency chromosome 12p genes during induced loss of
human embryonal carcinoma tumorigenicity. Biochim Biophys Acta
1731: 48-56. doi:10.1016/j.bbaexp.2005.08.006. PubMed: 16168501.
35. Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A et al.
(2009) High DNA methyltransferase 3B expression mediates 5-aza-
deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer
Res 69: 9360-9366. doi:10.1158/0008-5472.CAN-09-1490. PubMed:
19951990.
STK17A in Glioma
PLOS ONE | www.plosone.org 14 November 2013 | Volume 8 | Issue 11 | e81803
